Amicogen saw the highest growth of 0.39% in patent filings and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.39% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Amicogen’s patent filings and grants. Buy the databook here.
Amicogen has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 50% of filings. The European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Amicogen is filings its patents..
AbbVie and LG could be the strongest competitors for Amicogen
Paints and inks related patents lead Amicogen portfolio followed by abscess
Amicogen has highest number of patents in paints and inks followed by abscess.
For comprehensive analysis of Amicogen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.